Kite Announces Yescarta^® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

Kite, a Gilead Company announced top-line results from the primary analysis of ZUMA-7, a randomized Phase III global, multicenter study showing superiority of Yescarta® compared to standard of care in second-line relapsed or refractory large B-cell lymphoma.